Brief: Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-Study Data From The Lupkynis Aurora 2 Clinical Trial Presented At Congress Of Clinical Rheumatology East Conference
09/05/2023 11:21
May 9 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* AURINIA PHARMACEUTICALS ANNOUNCES KIDNEY BIOPSIES
SUB-STUDY DATA
FROM THE LUPKYNIS® (VOCLOSPORIN) AURORA 2 CLINICAL TRIAL
PRESENTED AT CONGRESS OF CLINICAL RHEUMATOLOGY EAST CONFERENCE
Source text for Eikon: ID:nBwbmJJbMa
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death